Karim Ahmed: Why The Right DOAC Choice Still Depends on The Patient
Karim Ahmed, Clinical Pharmacist at Palm Beach Accountable Care Organization, shared a post on LinkedIn:
“One thing pharmacy continues to reinforce for me is that even when two medications are in the same class, the best choice is rarely automatic.
I was recently reviewing a comparison of Eliquis (apixaban) and Xarelto (rivaroxaban), and it served as a great reminder of how much patient-specific decision-making still matters in anticoagulation.
Both are important DOAC options for AFib and VTE, but the differences in dosing, bleeding profile, renal considerations, and overall indication breadth can meaningfully shape the right choice in practice.
A few points stood out to me.
Xarelto offers the convenience of once-daily dosing and also has additional CAD/PAD indications.
Eliquis, on the other hand, is taken twice daily and appears to have a more favorable bleeding profile in some populations, including the newer evidence referenced in the article for VTE patients.
The renal piece is also important.
The article notes that Eliquis is generally preferred over Xarelto in stage 4-5 renal impairment because of its lower renal clearance, which is one of those practical distinctions that can make a real difference when evaluating therapy options.
My biggest takeaway is this: the better anticoagulant is often the one that best fits the patient’s full clinical picture – not just the diagnosis.
Adherence, renal function, bleeding risk, comorbidities, and drug interactions all matter.
That is where clinical judgment continues to make the biggest impact.
These kinds of comparisons are always a good reminder that individualized medication management remains at the center of good patient care.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation
-
Jul 8, 2026, 21:22What Hundreds of Stroke Stories Have Taught Diana Kerr About Recovery and Resilience – Stroke Foundation
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research